Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Amgen Inc. (AMGN) -- Ignore unavailable to you. Want to Upgrade?

To: JGoren who wrote (412)	12/2/1997 11:56:00 PM
From: Jacob Snyder	Read Replies (2) \| Respond to of 1906

RESEARCH ALERT - Amgen (NASDAQ:AMGN) started as hold Reuters, Tuesday, December 02, 1997 at 11:58 NEW YORK, Dec 2 (Reuters) - UBS Securities said on Tuesday it started coverage on shares of Amgen Inc with a neutral rating. -- Analyst Eric Schmidt said growth rates for the company's two blockbuster drugs, Epogen and Neupogen, have declined in recent years. -- "While each has the potential for further modest revenue growth, the company's pipeline is ill-prepared to make a meaningful contribution to future earnings," he said. -- Projects average annual Epogen sales growth of 10.7 percent through 2000. -- Sales of Neupogen increased by just nine percent in 1996. "Despite heightened competition and increased use of peripheral blood progenitor cell transplantation, sales could grow at a modest 6.2 percent annually for the 1997 to 2000 period," he said. -- Company's newest product, Infergen, is unlikely to differentiate itself from other approved interferons. -- Stock fell 1/16 to 52. Copyright 1997, Reuters News Service